JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, today announced the presentation of data from pre-clinical trials of BL-1021 at the Isranalytica meeting 2008 held in Tel Aviv, Israel, on January 22-23, 2008. Recent pre-clinical trials demonstrated that BL-1021 was safe and effective in pre-clinical testing for the treatment of neuropathic pain.
